Literature DB >> 20530415

Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation.

Linda Björkhem-Bergman1, Jure Acimovic, Ulla-Britta Torndal, Paolo Parini, Lennart C Eriksson.   

Abstract

AIM: This study tests the hypothesis that statins (HMGCoA reductase inhibitors) inhibit carcinogenesis and that this effect may be mediated by the statin-induced inhibition of ubiquinone synthesis.
MATERIALS AND METHODS: The effects of lovastatin, with and without addition of ubiquinone, were studied in a rat model for chemically induced hepatocarcinogenesis. Intermediates in the mevalonate pathway were measured.
RESULTS: Lovastatin treatment reduced the volume fraction of liver nodules by 50% and the cell proliferation within the liver nodules was reduced to one third. Ubiquinone (Q10) treatment reversed the statin-induced inhibition of cell proliferation. Lathosterol levels were reduced significantly in the statin-treated rats, indicating inhibition of the mevalonate pathway, but cholesterol levels were not affected.
CONCLUSION: Lovastatin inhibits carcinogenesis in a rat model for liver cancer, despite unaffected cholesterol levels. The statin-induced inhibition of cell proliferation may, at least in part, be explained by the inhibition of ubiquinone synthesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530415

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  What is a relevant statin concentration in cell experiments claiming pleiotropic effects?

Authors:  Linda Björkhem-Bergman; Jonatan D Lindh; Peter Bergman
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

2.  Statins are associated with reduced risk of gastric cancer: a meta-analysis.

Authors:  Xiao-Dan Wu; Kai Zeng; Fang-Qin Xue; Jin-Hua Chen; Yan-Qing Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

Review 3.  Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.

Authors:  Naomi Gronich; Gad Rennert
Journal:  Nat Rev Clin Oncol       Date:  2013-10-01       Impact factor: 66.675

4.  Studies on the antibacterial effects of statins--in vitro and in vivo.

Authors:  Peter Bergman; Charlotte Linde; Katrin Pütsep; Anton Pohanka; Staffan Normark; Birgitta Henriques-Normark; Jan Andersson; Linda Björkhem-Bergman
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

Review 5.  Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.

Authors:  Da-Zhi Liu; Bradley P Ander
Journal:  ScientificWorldJournal       Date:  2012-04-01

6.  Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation.

Authors:  Jonathan Vosper; Alessia Masuccio; Michael Kullmann; Christian Ploner; Stephan Geley; Ludger Hengst
Journal:  Oncotarget       Date:  2015-02-20

7.  Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.

Authors:  Heidrun Karlic; Roman Thaler; Christopher Gerner; Thomas Grunt; Katharina Proestling; Florian Haider; Franz Varga
Journal:  Cancer Genet       Date:  2015-03-18

8.  Chemically induced mouse liver tumors are resistant to treatment with atorvastatin.

Authors:  Albert Braeuning; Philip Bucher; Ute Hofmann; Albrecht Buchmann; Michael Schwarz
Journal:  BMC Cancer       Date:  2014-10-15       Impact factor: 4.430

9.  Chemopreventive efficacy of Atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties.

Authors:  Belmiro Parada; Flávio Reis; Ângela Pinto; José Sereno; Maria Xavier-Cunha; Paula Neto; Petronila Rocha-Pereira; Alfredo Mota; Arnaldo Figueiredo; Frederico Teixeira
Journal:  Int J Mol Sci       Date:  2012-07-09       Impact factor: 6.208

10.  Cholesterol-enriched membrane microdomains are needed for insulin signaling and proliferation in hepatic cells.

Authors:  Matheus de Castro Fonseca; Andressa França; Rodrigo Machado Florentino; Roberta Cristelli Fonseca; Antônio Carlos Melo Lima Filho; Paula Teixeira Vieira Vidigal; André Gustavo Oliveira; Laurent Dubuquoy; Michael H Nathanson; M Fátima Leite
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-22       Impact factor: 4.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.